Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae

Biochemical Pharmacology
N HaniokaS Narimatsu

Abstract

Cytochrome P450 2D6 (CYP2D6) metabolizes approximately one-third of the medicines in current clinical use and exhibits genetic polymorphism with interindividual differences in metabolic activity. To precisely investigate the effect of CYP2D6*10B and CYP2D6*36 frequently found in Oriental populations on mexiletine metabolism in vitro, CYP2D6 proteins of wild-type (CYP2D6.1) and variants (CYP2D6.10 and CYP2D6.36) were heterologously expressed in yeast cells and their mexiletine p- and 2-methyl hydroxylation activities were determined. Both variant CYP2D6 enzymes showed a drastic reduction of CYP2D6 holo- and apoproteins compared with those of CYP2D6.1. Mexiletine p- and 2-methyl hydroxylation activities on the basis of the microsomal protein level at the single substrate concentration (100 microM) of variant CYP2D6s were less than 6% for CYP2D6.10 and 1% for CYP2D6.36 of those of CYP2D6.1. Kinetic analysis for mexiletine hydroxylation revealed that the affinity toward mexiletine of CYP2D6.10 and CYP2D6.36 was reduced by amino acid substitutions. The Vmax and Vmax/Km values of CYP2D6.10 on the basis of the microsomal protein level were reduced to less than 10% of those of CYP2D6.1, whereas the values on the basis of functional CYP...Continue Reading

References

May 1, 1977·The Journal of Pharmacy and Pharmacology·A H Beckett, E C Chidomere
Aug 1, 1978·British Journal of Clinical Pharmacology·N P CampbellR G Shanks
May 1, 1984·American Heart Journal·R L WoosleyD Roden
Sep 1, 1995·Clinical Pharmacology and Therapeutics·M L LaiJ D Huang
Jan 22, 1998·Archives of Biochemistry and Biophysics·J WanY Funae
Aug 5, 1998·British Journal of Clinical Pharmacology·M NakajimaY Kuroiwa
May 1, 1999·Clinical Pharmacology and Therapeutics·J HuangM L Lai
May 8, 1999·British Journal of Clinical Pharmacology·T FukudaJ Azuma
Dec 10, 1999·Clinical Pharmacokinetics·L Labbé, J Turgeon
Jul 17, 2001·British Journal of Clinical Pharmacology·C SendaK Chiba
Mar 20, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nobumitsu HaniokaJun-ichi Sawada Ji
May 25, 2002·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·D F V Lewis
Sep 18, 2002·Biochemical Pharmacology·Hiroyuki HichiyaShizuo Narimatsu
Dec 5, 2002·Archives of Biochemistry and Biophysics·David F V Lewis
Jul 16, 2003·Nature·Pamela A WilliamsHarren Jhoti
Aug 26, 2003·European Journal of Clinical Pharmacology·Masahiro OtaniJunichi Azuma
Dec 17, 2003·The Journal of Biological Chemistry·Guillaume A SchochEric F Johnson
Dec 15, 2005·The Journal of Biological Chemistry·Paul RowlandAngela M Bridges

❮ Previous
Next ❯

Citations

Aug 12, 2010·European Journal of Clinical Pharmacology·Kazuma KiyotaniHiroshi Yamazaki
Nov 2, 2011·Drug Metabolism and Pharmacokinetics·Masahiro Hiratsuka
Feb 2, 2016·Chemico-biological Interactions·Yinsong ZhuHui Chen
May 12, 2010·Journal of Clinical Pharmacy and Therapeutics·Q LiS Wang
Sep 28, 2013·European Journal of Pharmacology·Constanze SchmidtDierk Thomas
Feb 18, 2017·Molecular Pharmaceutics·Jie GaoHai-Ling Qiao
Jan 30, 2007·Clinical Pharmacology and Therapeutics·A GaedigkJ Steven Leeder
Sep 12, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kanako SakuyamaMasahiro Hiratsuka
May 2, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Hongwu ShenChuan Li
Sep 16, 2014·Langmuir : the ACS Journal of Surfaces and Colloids·Dongmei CuiSongqin Liu
Sep 28, 2021·Pharmacogenomics·Maaike van der LeeJesse J Swen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antibody Repertoire Diversity

Antibody repertoire diversity and its role during natural infection is a prerequisite for molecular and structural elucidation of functionally protective immunity. Discover the latest insights into antibody diversity here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.